| [1] |
Xu L, Wu C, Li G. Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review [J]. J Nephrol, 2025, 38(6): 1557-1564.
|
| [2] |
中国医药卫生文化协会肾病与血液净化专业委员会. 原发性IgA肾病管理和治疗中国专家共识[J/OL]. 中华肾病研究电子杂志，2024, 13(1): 1-8.
|
| [3] |
Taguchi S, Hidaka S, Yanai M, et al. Renal hemosiderosis presenting with acute kidney injury and macroscopic hematuria in immunoglobulin A nephropathy: a case report [J]. BMC Nephrol, 2021, 22(1): 132.
|
| [4] |
Ni HF, Yang Y, Li CQ, et al. Myeloid bodies caused by COQ2 mutation: a case of concurrent COQ2 nephropathy and IgA nephropathy [J]. Clin Kidney J, 2021, 14(6): 1697-1700.
|
| [5] |
陈楠． 法布雷病：推动早期诊断和治疗，积极改善患者预后[J]. 中华内科杂志，2021, 60(4): 299-301.
|
| [6] |
Sun L, Zi X, Wang Z, et al. IgA nephropathy with mimicking Fabry disease: a case report and literature review [J]. Medicine (Baltimore), 2022, 101(42): e31060.
|
| [7] |
Hsu TR, Niu DM. Fabry disease: review and experience during newborn screening [J]. Trends Cardiovasc Med, 2018, 28(4): 274-281.
|
| [8] |
Michaud M, Mauhin W, Belmatoug N, et al. Fabry disease: a review[J]. Rev Med Interne, 2021, 42(2): 110-119.
|
| [9] |
Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility [J]. Kidney Int, 2009, 76(5): 546-556.
|
| [10] |
Sun L, Zi X, Wang Z, et al. IgA nephropathy with mimicking Fabry disease: a case report and literature review [J]. Medicine (Baltimore), 2022, 101(42): e31060.
|
| [11] |
Maixnerová D, Tesar V, Ryšavá R, et al. The coincidence of IgA nephropathy and Fabry disease [J]. BMC Nephrol, 2013, 14: 6.
|
| [12] |
Svarstad E, Marti HP. The changing landscape of Fabry disease [J]. Clin J Am Soc Nephrol, 2020, 15(4): 569-576.
|
| [13] |
Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry′s disease with the pharmacologic chaperone migalastat [J]. N Engl J Med, 2016, 375(6): 545-555.
|
| [14] |
Simonetta I, Tuttolomondo A, Di Chiara T, et al. Genetics and gene therapy of Anderson-Fabry disease [J]. Curr Gene Ther, 2018, 18(2): 96-106.
|